|
Chapter 1 Overview of Mechanisms of Defense |
|
|
1 | (16) |
|
Clinical Correlation: Simian Acquired Immune Deficiencies |
|
|
1 | (1) |
|
|
1 | (1) |
|
Essential Involvement of Animal Immune Systems in All Aspects of Animal Health |
|
|
1 | (1) |
|
|
2 | (14) |
|
|
3 | (1) |
|
Communication between Cells of the Immune System |
|
|
3 | (1) |
|
Communication through cytokines |
|
|
3 | (1) |
|
|
4 | (1) |
|
Communication through other signaling molecules |
|
|
4 | (1) |
|
Communication through cell--cell contact |
|
|
4 | (1) |
|
Innate and Adaptive Immune Systems |
|
|
5 | (1) |
|
|
5 | (4) |
|
|
9 | (7) |
|
Clinical Correlation Follow-Up |
|
|
16 | (1) |
|
|
16 | (1) |
|
|
16 | (1) |
|
Chapter 2 Overview of the Innate Immune System |
|
|
17 | (20) |
|
Clinical Correlation: Cyclic Neutropenia in Gray Collies |
|
|
17 | (1) |
|
|
17 | (1) |
|
Anatomical and Physiological Barriers to Microbial Invasion |
|
|
18 | (3) |
|
|
18 | (1) |
|
|
18 | (2) |
|
Mucus and Mucociliary Clearance |
|
|
20 | (1) |
|
|
21 | (1) |
|
Cells of the Innate Immune System |
|
|
21 | (4) |
|
|
21 | (2) |
|
Coordinating Hematopoiesis |
|
|
23 | (1) |
|
|
23 | (2) |
|
Overview of the Cells of the Innate Immune System |
|
|
25 | (8) |
|
Myeloid Innate Immune Cells |
|
|
25 | (1) |
|
|
25 | (1) |
|
|
26 | (1) |
|
|
27 | (1) |
|
|
28 | (1) |
|
|
29 | (1) |
|
|
30 | (1) |
|
|
31 | (1) |
|
Lymphoid Innate Immune Cells |
|
|
31 | (1) |
|
|
31 | (2) |
|
Other Innate Immune Cells |
|
|
33 | (1) |
|
Clinical Correlation: Follow-Up |
|
|
33 | (4) |
|
|
33 | (1) |
|
|
34 | (3) |
|
Chapter 3 Innate Immune Recognition |
|
|
37 | (16) |
|
Clinical Correlation: Sepsis in Neonatal Foals |
|
|
37 | (1) |
|
|
38 | (1) |
|
|
38 | (2) |
|
Evolutionarily Conserved Molecular Patterns |
|
|
40 | (1) |
|
Pathogen-Associated Molecular Patterns |
|
|
40 | (1) |
|
Pattern-Recognition Receptors |
|
|
40 | (6) |
|
Signaling Pattern-Recognition |
|
|
|
|
41 | (1) |
|
|
42 | (2) |
|
NOD-like receptors and RIG-like receptors |
|
|
44 | (1) |
|
Phagocytic Pattern-Recognition Receptors |
|
|
44 | (2) |
|
Other Pattern-Recognition Receptors |
|
|
46 | (1) |
|
Innate Recognition of Damage-Associated Molecular Patterns |
|
|
46 | (4) |
|
|
48 | (2) |
|
Consequences of Danger Signal Recognition by Sentinel Cells |
|
|
50 | (1) |
|
Activation of Macrophages |
|
|
50 | (1) |
|
Proinflammatory Mediators |
|
|
50 | (1) |
|
Clinical Correlation: Follow-Up |
|
|
50 | (3) |
|
|
50 | (1) |
|
|
51 | (2) |
|
Chapter 4 The Complement System |
|
|
53 | (14) |
|
Clinical Correlation: C3 Deficiency in Brittany Dogs |
|
|
53 | (1) |
|
|
53 | (1) |
|
|
54 | (6) |
|
|
55 | (2) |
|
|
57 | (1) |
|
|
58 | (2) |
|
Terminal Membrane Attack Pathway |
|
|
60 | (1) |
|
Regulation of Complement Activation |
|
|
60 | (2) |
|
Outcomes of Complement Activation |
|
|
62 | (2) |
|
Inflammation and Chemotaxis |
|
|
62 | (1) |
|
Enhancement of Phagocytosis (Opsonization) |
|
|
63 | (1) |
|
Promoting Humoral Immunity |
|
|
63 | (1) |
|
Clearance of Immune Complexes |
|
|
64 | (1) |
|
Clinical Correlation: Follow-Up |
|
|
64 | (3) |
|
|
64 | (1) |
|
|
64 | (3) |
|
Chapter 5 Acute Inflammation |
|
|
67 | (22) |
|
Clinical Correlation: Acute Bovine Mastitis |
|
|
67 | (1) |
|
|
67 | (1) |
|
Purposes of Acute Inflammation |
|
|
68 | (1) |
|
Signs of Acute Inflammation |
|
|
69 | (1) |
|
Initiators and Mediators of Acute Inflammation |
|
|
70 | (2) |
|
Vascular Changes in Acute Inflammation |
|
|
72 | (3) |
|
|
75 | (5) |
|
|
75 | (4) |
|
Diversity and Timeline of Leukocyte Recruitment |
|
|
79 | (1) |
|
Systemic Effects of Acute Inflammation |
|
|
80 | (5) |
|
Clinical Correlation Follow-Up |
|
|
85 | (4) |
|
|
86 | (1) |
|
|
86 | (3) |
|
Chapter 6 Innate Cellular Effector Mechanisms |
|
|
89 | (20) |
|
Clinical Correlation: Rattles in Foals |
|
|
89 | (1) |
|
|
90 | (1) |
|
Classification of Innate Cellular Effector Mechanisms |
|
|
90 | (1) |
|
Phagocytes and Phagocytosis |
|
|
91 | (8) |
|
Phagocytosis Part I Recognition and Adhesion of Particles on the Plasma Membrane of the Phagocyte |
|
|
91 | (3) |
|
Phagocytosis Part II Membrane and Cytoskeletal Reorganization to Mediate Particle Engulfment and the Creation of a Phagosome |
|
|
94 | (1) |
|
Phagocytosis Part III Maturation of the Phagosome into a Microbicidal and Degradative Phagolysosome |
|
|
94 | (5) |
|
Extracellular Innate Effector Mechanisms |
|
|
99 | (2) |
|
Degranulation by Neutrophils and Eosinophils |
|
|
99 | (1) |
|
Release of Neutrophil Extracellular Traps |
|
|
100 | (1) |
|
Natural Killer Cell---Mediated Cytotoxicity |
|
|
101 | (4) |
|
Recognition of Target Cells |
|
|
101 | (1) |
|
|
101 | (1) |
|
|
102 | (1) |
|
Targeted Degranulation by Natural Killer Cells |
|
|
102 | (3) |
|
Antibody-Dependent Cell-Mediated Cytotoxicity |
|
|
105 | (1) |
|
Clinical Correlation: Follow-Up |
|
|
105 | (4) |
|
|
105 | (1) |
|
|
106 | (3) |
|
Chapter 7 Cells and Organs of the Adaptive Immune System |
|
|
109 | (12) |
|
Clinical Correlation: Feline Lymphadenopathy |
|
|
109 | (1) |
|
|
109 | (1) |
|
Organs and Cells of the Adaptive Immune System |
|
|
109 | (10) |
|
Primary Lymphoid Organs and Hematopoiesis |
|
|
110 | (1) |
|
|
110 | (2) |
|
|
112 | (2) |
|
Secondary Lymphoid Organs |
|
|
114 | (1) |
|
|
115 | (2) |
|
|
117 | (1) |
|
Mucosa-associated lymphoid tissue |
|
|
118 | (1) |
|
Clinical Correlation: Follow-Up |
|
|
119 | (2) |
|
|
120 | (1) |
|
|
120 | (1) |
|
Chapter 8 Antigens and Antigen Processing |
|
|
121 | (22) |
|
Clinical Correlation: Caprine Arthritis Encephalitis |
|
|
121 | (1) |
|
|
122 | (1) |
|
Stimulators of Adaptive Immunity: Pathogens, Antigens, and Epitopes |
|
|
122 | (2) |
|
Major Histocompatibility Complex |
|
|
124 | (8) |
|
History of the Major Histocompatibility Complex |
|
|
124 | (1) |
|
Major Histocompatibility Complex Genetics |
|
|
125 | (4) |
|
Structure and Distribution of Major Histocompatibility Complex Class I and Class II Molecules |
|
|
129 | (2) |
|
Antigen---Major Histocompatibility Complex Interactions |
|
|
131 | (1) |
|
Antigen Acquisition, Processing, and Presentation |
|
|
132 | (7) |
|
|
132 | (3) |
|
Major Histocompatibility Complex Class I Antigen Processing and Presentation |
|
|
135 | (1) |
|
Major Histocompatibility Complex Class II Antigen Processing and Presentation |
|
|
136 | (1) |
|
|
137 | (2) |
|
Clinical Correlation: Follow-Up |
|
|
139 | (4) |
|
|
140 | (1) |
|
|
140 | (3) |
|
Chapter 9 T-Lymphocyte Development |
|
|
143 | (18) |
|
Clinical Correlation: Severe Combined Immunodeficiency Disease in Arabian Foals |
|
|
143 | (1) |
|
|
143 | (1) |
|
|
144 | (6) |
|
Structure of the T-Cell Receptor |
|
|
144 | (1) |
|
T-Cell Receptor Gene Families |
|
|
145 | (1) |
|
Gene Rearrangement in the Thymus |
|
|
145 | (5) |
|
T-Cell Selection in the Thymus |
|
|
150 | (8) |
|
Products of T-Cell Gene Rearrangement |
|
|
150 | (3) |
|
Positive Selection of Functional T Cells |
|
|
153 | (2) |
|
CD4, CD8, and Major Histocompatibility Complex Recognition |
|
|
155 | (1) |
|
Negative Selection of Self-Reactive T Cells |
|
|
155 | (1) |
|
T-Helper, Cytotoxic T, and T-Regulatory Cells |
|
|
156 | (1) |
|
|
156 | (2) |
|
Clinical Correlation: Follow-Up |
|
|
158 | (3) |
|
|
158 | (1) |
|
|
158 | (3) |
|
Chapter 10 T-Cell Activation |
|
|
161 | (20) |
|
Clinical Correlation: Canine X-Linked Severe Combined Immunodeficiency |
|
|
161 | (1) |
|
|
162 | (1) |
|
Antigen Recognition by T Cells |
|
|
162 | (7) |
|
First Signal: T-Cell Receptors and Major Histocompatibility Complex-Antigen Interactions |
|
|
162 | (2) |
|
Second Signal and Major Histocompatibility Complex-CD4/8 Interactions |
|
|
164 | (2) |
|
Signal Transduction and T-Cell Activation |
|
|
166 | (2) |
|
Third Signal and T-Helper Cell Differentiation |
|
|
168 | (1) |
|
|
169 | (12) |
|
Effector T-Helper Cells: Th1, Th2, Tfh, and Th17 Cells |
|
|
169 | (2) |
|
Effector Regulatory T Cells: Treg, Th3, and Tr1 Cells |
|
|
171 | (2) |
|
Effector Cytotoxic T Cells |
|
|
173 | (4) |
|
Clinical Correlation Follow-Up |
|
|
177 | (1) |
|
|
177 | (1) |
|
|
177 | (4) |
|
Chapter 11 B-Cell Development |
|
|
181 | (16) |
|
Clinical Correlation: Equine Agammaglobulinemia |
|
|
181 | (1) |
|
|
181 | (1) |
|
B Cells and the Structure of the B-Cell Receptor |
|
|
182 | (1) |
|
B-Cell Genetics, Development, and Circulation |
|
|
183 | (8) |
|
B-Cell Receptor Gene Families, Genetic Rearrangement, and Junctional Diversity |
|
|
183 | (3) |
|
Order and Regulation of B-Cell Development |
|
|
186 | (3) |
|
|
189 | (2) |
|
Other Populations of B Cells |
|
|
191 | (4) |
|
|
191 | (3) |
|
|
194 | (1) |
|
Clinical Correlation Follow-Up |
|
|
195 | (2) |
|
|
195 | (1) |
|
|
195 | (2) |
|
Chapter 12 B-Cell Activation and Differentiation |
|
|
197 | (22) |
|
Clinical Correlation: Selective Immunoglobulin A Deficiencies in Dogs |
|
|
197 | (1) |
|
|
197 | (2) |
|
T-Dependent B (B-2) Cells |
|
|
199 | (14) |
|
Interaction of B Cells with Antigens |
|
|
199 | (4) |
|
B Cells as Antigen-Presenting Cells |
|
|
203 | (1) |
|
Activation of B Cells by T-Helper Cells |
|
|
204 | (2) |
|
Isotype Switching, Somatic Hypermutation, and Terminal Differentiation of B Cells into Plasma Cells |
|
|
206 | (7) |
|
Antibody Effector Functions |
|
|
213 | (2) |
|
Pathogen and Toxin Neutralization |
|
|
213 | (1) |
|
Opsonization and Activation of Complement |
|
|
213 | (1) |
|
Distribution and Function of Fc Receptors |
|
|
214 | (1) |
|
Clinical Correlation Follow-Up |
|
|
215 | (4) |
|
|
215 | (2) |
|
|
217 | (2) |
|
Chapter 13 Adaptive Immune Responses to Infections and Immunological Memory |
|
|
219 | (22) |
|
Clinical Correlation: Canine Parvovirus and the Wolves of Isle Royale |
|
|
219 | (1) |
|
|
220 | (1) |
|
Adaptive Immunity: The Big Picture---From Insult to Recovery |
|
|
221 | (16) |
|
|
223 | (1) |
|
Mechanisms of Pathogenesis |
|
|
223 | (2) |
|
Innate Response Cells and Cytokines of Innate Responses Direct T-Cell Differentiation |
|
|
225 | (1) |
|
Effector T Cells Home to Sites of Infection and Inflammation |
|
|
226 | (3) |
|
Antibody Responses Develop in Secondary Lymphoid Tissues |
|
|
229 | (4) |
|
Importance of Different Adaptive Responses to Clearance of Different Pathogens |
|
|
233 | (1) |
|
Immune Responses in the Gut |
|
|
233 | (4) |
|
|
237 | (2) |
|
Primary and Subsequent Immune Reponses |
|
|
237 | (1) |
|
|
238 | (1) |
|
|
238 | (1) |
|
Clinical Correlation Follow-Up |
|
|
239 | (2) |
|
|
239 | (1) |
|
|
239 | (2) |
|
Chapter 14 Fetal and Neonatal Immunity |
|
|
241 | (12) |
|
Clinical Correlation: Failure of Passive Transfer |
|
|
241 | (1) |
|
|
241 | (1) |
|
Fetal Development of the Immune System |
|
|
241 | (2) |
|
Maternal Transfer of Immunity |
|
|
243 | (5) |
|
Prenatal Transfer of Immunity |
|
|
243 | (2) |
|
Postnatal Transfer of Immunity |
|
|
245 | (3) |
|
Neonatal Acquisition of Memory and Immune Capacity |
|
|
248 | (1) |
|
|
249 | (2) |
|
Clinical Correlation Follow-Up |
|
|
251 | (2) |
|
|
251 | (1) |
|
|
252 | (1) |
|
|
253 | (18) |
|
Clinical Correlation: Animal Vaccines |
|
|
253 | (1) |
|
|
253 | (1) |
|
|
253 | (14) |
|
|
253 | (2) |
|
|
255 | (4) |
|
|
259 | (1) |
|
Component, Toxoid, Conjugate, Recombinant, and Naked DNA Vaccines |
|
|
259 | (4) |
|
|
263 | (3) |
|
|
266 | (1) |
|
|
266 | (1) |
|
|
267 | (1) |
|
Clinical Correlation Follow-Up |
|
|
268 | (3) |
|
|
268 | (1) |
|
|
268 | (3) |
|
Chapter 16 Immune Deficiencies and Immune-Mediated Diseases |
|
|
271 | (16) |
|
Clinical Correlation: Feline Immunodeficiency Virus |
|
|
271 | (1) |
|
|
271 | (1) |
|
|
272 | (2) |
|
Congenital Immune Deficiencies |
|
|
272 | (1) |
|
Acquired Immune Deficiencies |
|
|
273 | (1) |
|
|
274 | (10) |
|
Hypersensitivities Type I, III, and IV |
|
|
274 | (1) |
|
Type I hypersensitivities |
|
|
274 | (5) |
|
Type III hypersensitivities |
|
|
279 | (3) |
|
Type IV hypersensitivities |
|
|
282 | (1) |
|
Type II Hypersensitivities and Autoimmune Diseases |
|
|
283 | (1) |
|
Clinical Correlation Follow-Up |
|
|
284 | (3) |
|
|
284 | (1) |
|
|
284 | (3) |
|
Chapter 17 The Immune System and Cancer |
|
|
287 | (8) |
|
Clinical Correlation: Canine Cancer |
|
|
287 | (1) |
|
|
287 | (1) |
|
|
287 | (2) |
|
Evidence That Mammalian Immune Systems Affect Tumors |
|
|
289 | (1) |
|
Tumor---Host Interactions |
|
|
290 | (2) |
|
|
292 | (1) |
|
Clinical Correlation: Follow-Up |
|
|
293 | (2) |
|
|
293 | (1) |
|
|
294 | (1) |
|
Chapter 18 Veterinary Clinical Laboratory Immunology |
|
|
295 | (24) |
|
Clinical Correlation: Transfusion Reactions |
|
|
295 | (2) |
|
|
297 | (1) |
|
Principles of Antibody-Based Techniques |
|
|
298 | (9) |
|
Generating Antibodies: Polyclonal and Monoclonal Antibodies |
|
|
298 | (1) |
|
Production of polyclonal antibodies |
|
|
298 | (1) |
|
Production of monoclonal antibodies |
|
|
299 | (1) |
|
Detecting Antibody--Antigen Reactions |
|
|
300 | (1) |
|
|
300 | (1) |
|
Enzyme-linked immunosorbent assays |
|
|
300 | (2) |
|
|
302 | (1) |
|
Immunofluorescent microscopy |
|
|
303 | (1) |
|
|
304 | (1) |
|
|
305 | (1) |
|
|
306 | (1) |
|
Diagnosis of Blood Type Incompatibilities |
|
|
307 | (5) |
|
|
307 | (1) |
|
|
308 | (1) |
|
|
308 | (1) |
|
|
309 | (1) |
|
|
309 | (3) |
|
Diagnosis of Immunodeficiencies |
|
|
312 | (1) |
|
Serum Immunoglobulin Quantification |
|
|
312 | (1) |
|
Phenotypic Analysis of Lymphocytes |
|
|
312 | (1) |
|
Other Immunodeficiency Tests |
|
|
313 | (1) |
|
Diagnosis of Autoimmunity |
|
|
313 | (6) |
|
Antinuclear Antibody Test |
|
|
313 | (1) |
|
|
314 | (1) |
|
Antiplatelet Antibody Test |
|
|
314 | (1) |
|
Antithyroglobulin Autoantibody Test |
|
|
315 | (1) |
|
Clinical Correlation: Follow-Up |
|
|
316 | (1) |
|
|
316 | (1) |
|
|
316 | (3) |
Glossary |
|
319 | (8) |
Index |
|
327 | |